Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide With or Without Celecoxib in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00538031Phase 2Completed
- Sponsor
- City of Hope
- Start
- Dec 2003
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of celecoxib oral solution in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by City of Hope. Primary endpoints: Overall Response up to 3 years, Time to Treatment Failure up to 3 years and 1 more. Started Dec 2003; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00538031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00538031.